Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Riddell (Dublin, Ireland). Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease. 898

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Source: Eur Respir J 2011; 38: 384-391 Year: 2011 Idiopathic inflammatory myopathies and the lung Source: Eur Respir Rev 2015; 24: 216-238 Year: 2015 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia Source: International Congress 2017 – Lung function testing Year: 2017 Interstitial lung diseases in childhood Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213 Year: 2002 Interstitial lung disease with autoimmune features Source: Eur Respir Mon 2011; 54: 104-117 Year: 2011 Immunogenetic background of children´s idiopathic interstitial pneumonias and adult idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Cytomegalovirus antigenemina in idiopathic interstitial pneumonias and collagen vascular disease-related lung diseases treated with immunosuppressive drugs Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Longitudinal clinico-physiological behaviour of interstitial lung disease in the idiopathic inflammatory muscle syndromes Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Clinical management of the idiopathic interstitial pneumonias: an example of an integrated approach to interstitial lung diseases Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias Year: 2006 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018 Novel markers of connective tissue disease in patients with idiopathic interstitial pneumonia Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Evaluation of interstitial inflammatory cell in idiopathic interstitial pneumonias Source: Eur Respir J 2006; 28: Suppl. 50, 99s Year: 2006